{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T15:40:41Z","timestamp":1780933241630,"version":"3.54.1"},"reference-count":153,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2025.12912","type":"journal-article","created":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T08:00:41Z","timestamp":1750838441000},"page":"1-14","source":"Crossref","is-referenced-by-count":1,"title":["Advancements and challenges in the management of obesity using pharmacotherapy (Review)"],"prefix":"10.3892","volume":"30","author":[{"given":"Saqer","family":"Alotaibi","sequence":"first","affiliation":[{"name":"Department of Biotechnology, College of Science, Taif University, Taif 21944, Kingdom of Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Essam","family":"Eldrehmy","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences, Turabah College, Taif University, Turabah 29734, Kingdom of Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Albogami","sequence":"additional","affiliation":[{"name":"Department of Biotechnology, College of Science, Taif University, Taif 21944, Kingdom of Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adel","family":"Alkhedaide","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Sciences, Turabah College, Taif University, Turabah 29734, Kingdom of Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omima","family":"Dahab","sequence":"additional","affiliation":[{"name":"Department of Biology, Turabah College, Taif University, Turabah 29734, Kingdom of Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"issue":"104754","key":"key20250710122437_b1-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2021.104754","article-title":"A systematic literature review on obesity: Understanding the causes & consequences of obesity and reviewing various machine learning approaches used to predict obesity","volume":"136","author":"Safaei","year":"2021","journal-title":"Comput Biol Med"},{"key":"key20250710122437_b2-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1017\/S0029665120000166","article-title":"Emotional eating and obesity in adults: The role of depression, sleep and genes","volume":"79","author":"Konttinen","year":"2020","journal-title":"Proc Nutr Soc"},{"key":"key20250710122437_b3-ETM-30-2-12912","author":"Tappia"},{"key":"key20250710122437_b4-ETM-30-2-12912","doi-asserted-by":"crossref","first-page":"90","DOI":"10.15406\/aowmc.2020.10.00312","article-title":"The causes of obesity: An in-depth review","volume":"10","author":"Omer","year":"2020","journal-title":"Adv Obes Weight Manag Control"},{"key":"key20250710122437_b5-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1093\/aje\/kwm226","article-title":"Impact of energy intake, physical activity, and population-wide weight loss on cardiovascular disease and diabetes mortality in Cuba, 1980-2005","volume":"166","author":"Franco","year":"2007","journal-title":"Am J Epidemiol"},{"issue":"10449","key":"key20250710122437_b6-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310449","article-title":"Emerging role of GLP-1 agonists in obesity: A comprehensive review of randomised controlled trials","volume":"24","author":"Popoviciu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"key20250710122437_b7-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.2337\/diacare.28.9.2322","article-title":"Point: Visceral adiposity is causally related to insulin resistance","volume":"28","author":"Lebovitz","year":"2005","journal-title":"Diabetes Care"},{"key":"key20250710122437_b8-ETM-30-2-12912","author":"Crowley"},{"key":"key20250710122437_b9-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature05485","article-title":"Inflammation and metabolic disorders","volume":"444","author":"Hotamisligil","year":"2006","journal-title":"Nature"},{"key":"key20250710122437_b10-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/jcp.25855","article-title":"Adipocytes properties and crosstalk with immune system in obesity-related inflammation","volume":"233","author":"Maurizi","year":"2018","journal-title":"J Cell Physiol"},{"key":"key20250710122437_b11-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature10986","article-title":"A novel ChREBP isoform in adipose tissue regulates systemic glucose metabolism","volume":"484","author":"Herman","year":"2012","journal-title":"Nature"},{"key":"key20250710122437_b12-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1385\/ENDO:13:2:155","article-title":"Metabolic complications of obesity","volume":"13","author":"Grundy","year":"2000","journal-title":"Endocrine"},{"key":"key20250710122437_b13-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s11154-021-09699-1","article-title":"Semaglutide, a glucagon like peptide-1 receptor agonist with cardiovascular benefits for management of type 2 diabetes","volume":"23","author":"Mahapatra","year":"2022","journal-title":"Rev Endocr Metab Disord"},{"key":"key20250710122437_b14-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"629","DOI":"10.3945\/jn.108.097618","article-title":"Homeostatic and hedonic signals interact in the regulation of food intake","volume":"139","author":"Lutter","year":"2009","journal-title":"J Nutr"},{"key":"key20250710122437_b15-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"11469","DOI":"10.1523\/JNEUROSCI.2338-16.2016","article-title":"Homeostasis meets motivation in the battle to control food intake","volume":"36","author":"Ferrario","year":"2016","journal-title":"J Neurosci"},{"key":"key20250710122437_b16-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1172\/jci110846","article-title":"Stimulation of thermogenesis by carbohydrate overfeeding. Evidence against sympathetic nervous system mediation","volume":"71","author":"Welle","year":"1983","journal-title":"J Clin Invest"},{"key":"key20250710122437_b17-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1126\/science.867049","article-title":"Suppression of sympathetic nervous system during fasting","volume":"5","author":"Young","year":"1997","journal-title":"Obes Res"},{"key":"key20250710122437_b18-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.euroneuro.2014.05.005","article-title":"Association of central serotonin transporter availability and body mass index in healthy Europeans","volume":"24","author":"Hesse","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"issue":"919","key":"key20250710122437_b19-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2014.00919","article-title":"Dopamine and glucose, obesity, and reward deficiency syndrome","volume":"5","author":"Blum","year":"2014","journal-title":"Front Psychol"},{"issue":"2984","key":"key20250710122437_b20-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.87.6.8738","article-title":"Food fails to suppress ghrelin levels in obese humans","volume":"87","author":"English","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"key20250710122437_b21-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1172\/JCI9842","article-title":"Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity","volume":"105","author":"El-Haschimi","year":"2000","journal-title":"J Clin Invest"},{"key":"key20250710122437_b22-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1210\/jc.2014-3415","article-title":"Pharmacological management of obesity: An endocrine society clinical practice guideline","volume":"100","author":"Apovian","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"key20250710122437_b23-ETM-30-2-12912"},{"key":"key20250710122437_b24-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1056\/NEJMc2010419","article-title":"Clinical characteristics of Covid-19 in New York city","volume":"382","author":"Goyal","year":"2020","journal-title":"N Engl J Med"},{"key":"key20250710122437_b25-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/s41366-020-0648-x","article-title":"The impact of obesity on COVID-19 complications: A retrospective cohort study","volume":"44","author":"Nakeshbandi","year":"2020","journal-title":"Int J Obes (Lond)"},{"key":"key20250710122437_b26-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4137\/BMI.S19876","article-title":"Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population","volume":"9","author":"Haupt","year":"2014","journal-title":"Biomark Insights"},{"issue":"e0245424","key":"key20250710122437_b27-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0245424","article-title":"Influence of obesity on serum levels of SARS-CoV-2-specific antibodies in COVID-19 patients","volume":"16","author":"Frasca","year":"2021","journal-title":"PLoS One"},{"key":"key20250710122437_b28-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/304368a0","article-title":"Exon duplication and divergence in the human preproglucagon gene","volume":"304","author":"Bell","year":"1983","journal-title":"Nature"},{"key":"key20250710122437_b29-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1056\/NEJM199205143262003","article-title":"Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus","volume":"326","author":"Gutniak","year":"1992","journal-title":"N Engl J Med"},{"key":"key20250710122437_b30-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-6736(08)61206-4","article-title":"Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: A randomised, open-label, non-inferiority study","volume":"372","author":"Drucker","year":"2008","journal-title":"Lancet"},{"key":"key20250710122437_b31-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol Metab"},{"key":"key20250710122437_b32-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1172\/JCI116186","article-title":"Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus","volume":"91","author":"Nauck","year":"1993","journal-title":"J Clin Invest"},{"key":"key20250710122437_b33-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1111\/joim.13433","article-title":"Glucagon-like peptide-1: Are its roles as endogenous hormone and therapeutic wizard congruent?","volume":"291","author":"Holst","year":"2022","journal-title":"J Intern Med"},{"issue":"9936","key":"key20250710122437_b34-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22189936","article-title":"Oral semaglutide, the first ingestible glucagon-like peptide-1 receptor agonist: Could it be a magic bullet for type 2 diabetes?","volume":"22","author":"Kim","year":"2021","journal-title":"Int J Mol Sci"},{"key":"key20250710122437_b35-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s41591-021-01391-w","article-title":"Danuglipron (PF-06882961) in type 2 diabetes: A randomized, placebo-controlled, multiple ascending-dose phase 1 trial","volume":"27","author":"Saxena","year":"2021","journal-title":"Nat Med"},{"issue":"108904","key":"key20250710122437_b36-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108904","article-title":"Comparative efficacy and safety of 8 GLP-1RAs in patients with type 2 diabetes: A network meta-analysis","volume":"177","author":"Xia","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"issue":"e133429","key":"key20250710122437_b37-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133429","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2020","journal-title":"JCI Insight"},{"key":"key20250710122437_b38-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1172\/JCI75276","article-title":"The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss","volume":"124","author":"Secher","year":"2014","journal-title":"J Clin Invest"},{"key":"key20250710122437_b39-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/joim.12837","article-title":"Peptide-based multi-agonists: A new paradigm in metabolic pharmacology","volume":"284","author":"Brandt","year":"2018","journal-title":"J Intern Med"},{"key":"key20250710122437_b40-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/oby.22726","article-title":"Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: The SCALE IBT randomized controlled trial","volume":"28","author":"Wadden","year":"2020","journal-title":"Obesity (Silver Spring)"},{"key":"key20250710122437_b41-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","article-title":"Anti-obesity drug discovery: Advances and challenges","volume":"21","author":"M\u00fcller","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"key20250710122437_b42-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/14656566.2019.1695779","article-title":"An evaluation of liraglutide including its efficacy and safety for the treatment of obesity","volume":"21","author":"Lin","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"key20250710122437_b43-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1517\/14712598.2011.583641","article-title":"Liraglutide for type 2 diabetes mellitus","volume":"11","author":"Kela","year":"2011","journal-title":"Expert Opin Biol Ther"},{"key":"key20250710122437_b44-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.2165\/11592810-000000000-00000","article-title":"Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: Current and emerging agents","volume":"71","author":"Gallwitz","year":"2011","journal-title":"Drugs"},{"key":"key20250710122437_b45-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 Years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: A randomised, double-blind trial","volume":"389","author":"Le Roux","year":"2017","journal-title":"Lancet"},{"key":"key20250710122437_b46-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"bqaa093","key":"key20250710122437_b47-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.1210\/endocr\/bqaa093","article-title":"A role for GLP-1 in treating hyperphagia and obesity","volume":"161","author":"Grill","year":"2020","journal-title":"Endocrinology"},{"key":"key20250710122437_b48-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s40262-018-0668-z","article-title":"Pharmacokinetics and clinical implications of semaglutide: A new glucagon-like peptide (GLP)-1 receptor agonist","volume":"57","author":"Hall","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"key20250710122437_b49-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/obr.12839","article-title":"Semaglutide as a promising antiobesity drug","volume":"20","author":"Christou","year":"2019","journal-title":"Obes Rev"},{"key":"key20250710122437_b50-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"155","key":"key20250710122437_b51-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"key20250710122437_b52-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.2337\/dc23-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2023","volume":"46 (Suppl 1)","author":"ElSayed","year":"2023","journal-title":"Diabetes Care"},{"key":"key20250710122437_b53-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J Med Chem"},{"issue":"eaar7047","key":"key20250710122437_b54-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aar7047","article-title":"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci Transl Med"},{"key":"key20250710122437_b55-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"key":"key20250710122437_b56-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"key":"key20250710122437_b57-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: A randomized clinical trial","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA"},{"key":"key20250710122437_b58-ETM-30-2-12912","author":"Reusch"},{"key":"key20250710122437_b59-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"832","DOI":"10.2337\/diab.45.6.832","article-title":"Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I","volume":"45","author":"\u00d8rskov","year":"1996","journal-title":"Diabetes"},{"key":"key20250710122437_b60-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.2337\/dc09-0366","article-title":"Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: A randomized controlled trial exploring weekly, biweekly, and monthly dosing","volume":"32","author":"Rosenstock","year":"2009","journal-title":"Diabetes Care"},{"key":"key20250710122437_b61-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/dmrr.1080","article-title":"Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein","volume":"26","author":"Glaesner","year":"2010","journal-title":"Diabetes Metab Res Rev"},{"key":"key20250710122437_b62-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.cmet.2021.01.015","article-title":"The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling","volume":"33","author":"Zhang","year":"2021","journal-title":"Cell Metab"},{"key":"key20250710122437_b63-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1463-1326.2011.01365.x","article-title":"LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects","volume":"13","author":"Barrington","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"key20250710122437_b64-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/j.1463-1326.2011.01366.x","article-title":"The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight\/obese patients with type 2 diabetes: The EGO study","volume":"13","author":"Umpierrez","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"key20250710122437_b65-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/oby.2004.76","article-title":"Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients","volume":"12","author":"Hollander","year":"2004","journal-title":"Obes Res"},{"key":"key20250710122437_b66-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: A randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"key":"key20250710122437_b67-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.molmet.2017.11.009","article-title":"Amylin-its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity","volume":"8","author":"Boyle","year":"2018","journal-title":"Mol Metab"},{"key":"key20250710122437_b68-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"944","DOI":"10.2174\/1389203720666190328111833","article-title":"Human amylin: From pathology to physiology and pharmacology","volume":"20","author":"Ling","year":"2019","journal-title":"Curr Protein Pept Sci"},{"key":"key20250710122437_b69-ETM-30-2-12912","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/14746514050050030701","article-title":"Amylin analogue as an antidiabetic agent","volume":"5","author":"Day","year":"2005","journal-title":"Br J Diabetes Vasc Dis"},{"key":"key20250710122437_b70-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/oby.2009.184","article-title":"Enhanced weight loss with pramlintide\/metreleptin: An integrated neurohormonal approach to obesity pharmacotherapy","volume":"17","author":"Ravussin","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"key20250710122437_b71-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"11183","DOI":"10.1021\/acs.jmedchem.1c00565","article-title":"Development of cagrilintide, a long-acting amylin analogue","volume":"64","author":"Kruse","year":"2021","journal-title":"J Med Chem"},{"key":"key20250710122437_b72-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: A multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial","volume":"398","author":"Lau","year":"2021","journal-title":"Lancet"},{"key":"key20250710122437_b73-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"445","DOI":"10.4103\/ijem.ijem_442_23","article-title":"Approved and emerging hormone-based anti-obesity medications: A review article","volume":"28","author":"Sidrak","year":"2024","journal-title":"Indian J Endocrinol Metab"},{"key":"key20250710122437_b74-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.1172\/JCI126107","article-title":"Gut-derived GIP activates central Rap1 to impair neural leptin sensitivity during overnutrition","volume":"129","author":"Kaneko","year":"2019","journal-title":"J Clin Invest"},{"key":"key20250710122437_b75-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.molmet.2018.12.001","article-title":"Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism","volume":"20","author":"Mroz","year":"2019","journal-title":"Mol Metab"},{"key":"key20250710122437_b76-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.cmet.2019.07.013","article-title":"Glucose-dependent insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake","volume":"30","author":"Adriaenssens","year":"2019","journal-title":"Cell Metab"},{"issue":"107768","key":"key20250710122437_b77-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107768","article-title":"Corrination of a GLP-1 receptor agonist for glycemic control without emesis","volume":"31","author":"Borner","year":"2020","journal-title":"Cell Rep"},{"key":"key20250710122437_b78-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How may GIP enhance the therapeutic efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol Metab"},{"key":"key20250710122437_b79-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"e2710","DOI":"10.1210\/clinem\/dgaa327","article-title":"GIP as a therapeutic target in diabetes and obesity: Insight from incretin co-agonists","volume":"105","author":"Holst","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"key20250710122437_b80-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): A double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"key20250710122437_b81-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1042\/bj2860737","article-title":"Expression of ileal glucagon and peptide tyrosine-tyrosine genes. Response to inhibition of polyamine synthesis in the presence of massive small-bowel resection","volume":"286","author":"Taylor","year":"1992","journal-title":"Biochem J"},{"key":"key20250710122437_b82-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s004240050913","article-title":"Comparison of the postprandial release of peptide YY and proglucagon-derived peptides in the rat","volume":"438","author":"Anini","year":"1999","journal-title":"Pflugers Arch"},{"key":"key20250710122437_b83-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/j.1365-2362.1988.tb01046.x","article-title":"Oxyntomodulin: A potential hormone from the distal gut. Pharmacokinetics and effects on gastric acid and insulin secretion in man","volume":"18","author":"Schjoldager","year":"1988","journal-title":"Eur J Clin Invest"},{"key":"key20250710122437_b84-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1080\/003655201750422710","article-title":"Effect of circulating peptide YY on gallbladder emptying in humans","volume":"36","author":"Hoentjen","year":"2001","journal-title":"Scand J Gastroenterol"},{"key":"key20250710122437_b85-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1038\/sj.ijo.0801912","article-title":"Glucagon-like peptide containing pathways in the regulation of feeding behaviour","volume":"25 (Suppl 5)","author":"Tang-Christensen","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"key":"key20250710122437_b86-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/s1043-2760(99)00157-5","article-title":"Glucagon-like peptide 1 (GLP-1): An intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential","volume":"10","author":"Holst","year":"1999","journal-title":"Trends Endocrinol Metab"},{"key":"key20250710122437_b87-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/BF00252412","article-title":"Glucagon-related peptides in the human gastrointestinal mucosa","volume":"26","author":"Baldissera","year":"1984","journal-title":"Diabetologia"},{"key":"key20250710122437_b88-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/bip.360220138","article-title":"Conformational flexibility in a small globular hormone: X-ray analysis of avian pancreatic polypeptide at 0.98-A resolution","volume":"22","author":"Glover","year":"1983","journal-title":"Biopolymers"},{"key":"key20250710122437_b89-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/0016-5085(85)90211-2","article-title":"Human distribution and release of a putative new gut hormone, peptide YY","volume":"89","author":"Adrian","year":"1985","journal-title":"Gastroenterology"},{"key":"key20250710122437_b90-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/s0196-9781(01)00601-5","article-title":"Distribution of pancreatic polypeptide and peptide YY","volume":"23","author":"Ekblad","year":"2002","journal-title":"Peptides"},{"key":"key20250710122437_b91-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1002\/oby.23374","article-title":"Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss","volume":"30","author":"Christoffersen","year":"2022","journal-title":"Obesity (Silver Spring)"},{"key":"key20250710122437_b92-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nm.3761","article-title":"A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents","volume":"21","author":"Finan","year":"2015","journal-title":"Nat Med"},{"key":"key20250710122437_b93-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/s41586-024-08207-0","article-title":"NK2R control of energy expenditure and feeding to treat metabolic diseases","volume":"635","author":"Sass","year":"2024","journal-title":"Nature"},{"key":"key20250710122437_b94-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s42255-023-00782-2","article-title":"Total daily energy expenditure has declined over the past three decades due to declining basal expenditure, not reduced activity expenditure","volume":"5","author":"Speakman","year":"2023","journal-title":"Nat Metab"},{"key":"key20250710122437_b95-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1038\/nrd.2017.178","article-title":"Trends in GPCR drug discovery: New agents, targets and indications","volume":"16","author":"Hauser","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"key20250710122437_b96-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1113\/jphysiol.1970.sp009155","article-title":"Further purification of a polypeptide demonstrating enterogastrone activity","volume":"209","author":"Brown","year":"1970","journal-title":"J Physiol"},{"key":"key20250710122437_b97-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: A 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse","year":"2009","journal-title":"Lancet"},{"key":"key20250710122437_b98-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus","volume":"8","author":"Meier","year":"2012","journal-title":"Nat Rev Endocrinol"},{"key":"key20250710122437_b99-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"key":"key20250710122437_b100-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJMc2211120","article-title":"Tirzepatide once weekly for the treatment of obesity. Reply","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"key20250710122437_b101-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"key":"key20250710122437_b102-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"key":"key20250710122437_b103-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"4449","DOI":"10.2147\/DDDT.S365416","article-title":"Clinical insight on semaglutide for chronic weight management in adults: Patient selection and special considerations","volume":"16","author":"Chao","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"key20250710122437_b104-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"key20250710122437_b105-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/cen.15133","article-title":"Anti-obesity medication in the management of children and adolescents with obesity: Recent developments and research gaps","volume":"102","author":"Torbahn","year":"2025","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"e13113","key":"key20250710122437_b106-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.13113","article-title":"Pharmacological interventions for the management of children and adolescents living with obesity-An update of a Cochrane systematic review with meta-analyses","volume":"19","author":"Torbahn","year":"2024","journal-title":"Pediatr Obes"},{"key":"key20250710122437_b107-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1136\/archdischild-2023-326687","article-title":"Semaglutide treatment for children with obesity: An observational study","volume":"109","author":"van Boxel","year":"2024","journal-title":"Arch Dis Child"},{"issue":"907750","key":"key20250710122437_b108-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.907750","article-title":"Obesity, inflammation, and immune system in osteoarthritis","volume":"13","author":"Nedunchezhiyan","year":"2022","journal-title":"Front Immunol"},{"key":"key20250710122437_b109-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1161\/01.cir.0000437739.71477.ee","article-title":"2013 AHA\/ACC\/TOS guideline for the management of overweight and obesity in adults: A report of the American college of cardiology\/American heart association task force on practice guidelines and the obesity society","volume":"129 (Suppl 2)","author":"Jensen","year":"2014","journal-title":"Circulation"},{"key":"key20250710122437_b110-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s13679-017-0262-y","article-title":"Weight loss and improvement in comorbidity: Differences at 5, 10, 15%, and over","volume":"6","author":"Ryan","year":"2017","journal-title":"Curr Obes Rep"},{"issue":"1305","key":"key20250710122437_b111-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.3390\/cells8111305","article-title":"Articular cartilage regeneration in osteoarthritis","volume":"8","author":"Roseti","year":"2019","journal-title":"Cells"},{"key":"key20250710122437_b112-ETM-30-2-12912","author":"Moiz"},{"key":"key20250710122437_b113-ETM-30-2-12912","author":"Petrongolo"},{"issue":"991","key":"key20250710122437_b114-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.3390\/ph14100991","article-title":"Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized phase II\/III trials","volume":"14","author":"Bhagavathula","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"key20250710122437_b115-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: The SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"issue":"118","key":"key20250710122437_b116-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-025-02647-2","article-title":"Correction: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and cardiometabolic protection: Historical development and future challenges","volume":"24","author":"Westermeier","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"key20250710122437_b117-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2337\/dci17-0057","article-title":"Cardiovascular outcomes trials in type 2 diabetes: Where do we go from here? Reflections from a diabetes care editors' expert forum","volume":"41","author":"Cefalu","year":"2018","journal-title":"Diabetes Care"},{"key":"key20250710122437_b118-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"key20250710122437_b119-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/bph.15462","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits-The role of the GLP-1 receptor","volume":"179","author":"Helmst\u00e4dter","year":"2022","journal-title":"Br J Pharmacol"},{"key":"key20250710122437_b120-ETM-30-2-12912","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European SOCIETY OF CARDIOlogy (ESC)","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"key20250710122437_b121-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.2337\/dc20-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes-2020","volume":"43 (Suppl 1)","year":"2020","journal-title":"Diabetes Care"},{"issue":"599646","key":"key20250710122437_b122-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2020.599646","article-title":"Long-acting glucagon-like peptide-1 receptor agonists suppress voluntary alcohol intake in male wistar rats","volume":"14","author":"Marty","year":"2020","journal-title":"Front Neurosci"},{"key":"key20250710122437_b123-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders","volume":"179","author":"Klausen","year":"2022","journal-title":"Br J Pharmacol"},{"key":"key20250710122437_b124-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/mp.2012.141","article-title":"GLP-1 analog attenuates cocaine reward","volume":"18","author":"Graham","year":"2013","journal-title":"Mol Psychiatry"},{"issue":"e69010","key":"key20250710122437_b125-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0069010","article-title":"The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice","volume":"8","author":"Egecioglu","year":"2013","journal-title":"PLoS One"},{"key":"key20250710122437_b126-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.physbeh.2012.03.014","article-title":"Exendin-4 decreases amphetamine-induced locomotor activity","volume":"106","author":"Erreger","year":"2012","journal-title":"Physiol Behav"},{"issue":"109872","key":"key20250710122437_b127-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2020.109872","article-title":"The GLP-1 receptor agonist liraglutide reverses mania-like alterations and memory deficits induced by D-amphetamine and augments lithium effects in mice: Relevance for bipolar disorder","volume":"99","author":"Chaves Filho","year":"2020","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"key20250710122437_b128-ETM-30-2-12912","first-page":"282","article-title":"Hyperlipidemia in Saudi Arabia","volume":"29","author":"Al-Nozha","year":"2008","journal-title":"Saudi Med J"},{"issue":"8074837","key":"key20250710122437_b129-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8074837","article-title":"Prevalence of obesity and overweight among adults in the Middle East countries from 2000 to 2020: A systematic review and meta-analysis","volume":"2022","author":"Okati-Aliabad","year":"2022","journal-title":"J Obes"},{"key":"key20250710122437_b130-ETM-30-2-12912","doi-asserted-by":"crossref","first-page":"590","DOI":"10.4236\/ijcm.2022.1312045","article-title":"Clinical practice guideline for the management of overweight and obesity in adults in Saudi Arabia","volume":"13","author":"Alshaikh","year":"2022","journal-title":"Int J Clin Med"},{"key":"key20250710122437_b131-ETM-30-2-12912"},{"issue":"E174","key":"key20250710122437_b132-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.5888\/pcd11.140236","article-title":"Obesity and associated factors-Kingdom of Saudi Arabia, 2013","volume":"11","author":"Memish","year":"2014","journal-title":"Prev Chronic Dis"},{"issue":"102192","key":"key20250710122437_b133-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsps.2024.102192","article-title":"A systematic review of obesity burden in Saudi Arabia: Prevalence and associated co-morbidities","volume":"32","author":"Al-Omar","year":"2024","journal-title":"Saudi Pharm J"},{"key":"key20250710122437_b134-ETM-30-2-12912","first-page":"401","article-title":"Prevalence of obesity among military personnel in Saudi Arabia and associated risk factors","volume":"34","author":"Bin Horaib","year":"2013","journal-title":"Saudi Med J"},{"issue":"e0264993","key":"key20250710122437_b135-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264993","article-title":"The economic burden of overweight and obesity in Saudi Arabia","volume":"17","author":"Malkin","year":"2022","journal-title":"PLoS One"},{"key":"key20250710122437_b136-ETM-30-2-12912","author":"Alluhidan"},{"key":"key20250710122437_b137-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"230","DOI":"10.26719\/emhj.18.034","article-title":"Compliance with school nutrition policy in Saudi Arabia: A quantitative study","volume":"25","author":"Aldubayan","year":"2019","journal-title":"East Mediterr Health J"},{"key":"key20250710122437_b138-ETM-30-2-12912","author":"Gerich"},{"key":"key20250710122437_b139-ETM-30-2-12912"},{"key":"key20250710122437_b140-ETM-30-2-12912"},{"key":"key20250710122437_b141-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1111\/j.1464-5491.2012.03699.x","article-title":"Exenatide plus metformin compared with metformin alone on \u03b2-cell function in patients with Type 2 diabetes","volume":"29","author":"Derosa","year":"2012","journal-title":"Diabet Med"},{"key":"key20250710122437_b142-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/dom.12849","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis","volume":"19","author":"Htike","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"key20250710122437_b143-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1111\/dom.16162","article-title":"Weight loss and body composition after compounded semaglutide treatment in a real world setting","volume":"27","author":"Chun","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"key20250710122437_b144-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s13300-014-0058-y","article-title":"Choosing appropriate glucagon-like peptide 1 receptor agonists: A patient-centered approach","volume":"5","author":"Kalra","year":"2014","journal-title":"Diabetes Ther"},{"key":"key20250710122437_b145-ETM-30-2-12912","author":"GlaxoSmithKline"},{"key":"key20250710122437_b146-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40262-015-0338-3","article-title":"Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: Analyses of data from clinical trials","volume":"55","author":"Geiser","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"key20250710122437_b147-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1016\/j.clinthera.2009.11.034","article-title":"A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus","volume":"31","author":"Montanya","year":"2009","journal-title":"Clin Ther"},{"key":"key20250710122437_b148-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: A randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil","year":"2018","journal-title":"Lancet"},{"key":"key20250710122437_b149-ETM-30-2-12912","first-page":"227","article-title":"Liraglutide (Saxenda\u00ae) as a treatment for obesity","volume":"7","author":"Onge","year":"2016","journal-title":"Food Nutr Sci"},{"issue":"4315","key":"key20250710122437_b150-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27134315","article-title":"Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: A mini-review","volume":"27","author":"Chavda","year":"2022","journal-title":"Molecules"},{"issue":"1277113","key":"key20250710122437_b151-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2024.1277113","article-title":"Tirzepatide as a novel effective and safe strategy for treating obesity: A systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Cai","year":"2024","journal-title":"Front Public Health"},{"issue":"4346","key":"key20250710122437_b152-ETM-30-2-12912","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084346","article-title":"Assessment of thyroid carcinogenic risk and safety profile of GLP1-RA semaglutide (Ozempic) therapy for diabetes mellitus and obesity: A systematic literature review","volume":"25","author":"Feier","year":"2024","journal-title":"Int J Mol Sci"},{"key":"key20250710122437_b153-ETM-30-2-12912","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.2147\/DDDT.S470826","article-title":"Clinical pharmacokinetics of semaglutide: A systematic review","volume":"18","author":"Yang","year":"2024","journal-title":"Drug Des Devel Ther"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T09:24:44Z","timestamp":1752139484000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2025.12912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":153,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,6,25]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2025.12912","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]}}}